HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT.

AbstractBACKGROUND:
Knee osteoarthritis (OA) is a major cause of pain and functional limitation in older adults, yet longer-term studies of medical treatment of OA are limited.
OBJECTIVE:
To evaluate the efficacy and safety of glucosamine and chondroitin sulphate (CS), alone or in combination, as well as celecoxib and placebo on painful knee OA over 2 years.
METHODS:
A 24-month, double-blind, placebo-controlled study, conducted at nine sites in the US ancillary to the Glucosamine/chondroitin Arthritis Intervention Trial, enrolled 662 patients with knee OA who satisfied radiographic criteria (Kellgren/Lawrence grade 2 or 3 changes and baseline joint space width of at least 2 mm). This subset continued to receive their randomised treatment: glucosamine 500 mg three times daily, CS 400 mg three times daily, the combination of glucosamine and CS, celecoxib 200 mg daily, or placebo over 24 months. The primary outcome was a 20% reduction in Western Ontario and McMaster University Osteoarthritis Index (WOMAC) pain over 24 months. Secondary outcomes included an Outcome Measures in Rheumatology/Osteoarthritis Research Society International response and change from baseline in WOMAC pain and function.
RESULTS:
Compared with placebo, the odds of achieving a 20% reduction in WOMAC pain were celecoxib: 1.21, glucosamine: 1.16, combination glucosamine/CS: 0.83 and CS alone: 0.69, and were not statistically significant.
CONCLUSIONS:
Over 2 years, no treatment achieved a clinically important difference in WOMAC pain or function as compared with placebo. However, glucosamine and celecoxib showed beneficial but not significant trends. Adverse reactions were similar among treatment groups and serious adverse events were rare for all treatments.
AuthorsAllen D Sawitzke, Helen Shi, Martha F Finco, Dorothy D Dunlop, Crystal L Harris, Nora G Singer, John D Bradley, David Silver, Christopher G Jackson, Nancy E Lane, Chester V Oddis, Fred Wolfe, Jeffrey Lisse, Daniel E Furst, Clifton O Bingham, Domenic J Reda, Roland W Moskowitz, H James Williams, Daniel O Clegg
JournalAnnals of the rheumatic diseases (Ann Rheum Dis) Vol. 69 Issue 8 Pg. 1459-64 (Aug 2010) ISSN: 1468-2060 [Electronic] England
PMID20525840 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
Chemical References
  • Cyclooxygenase 2 Inhibitors
  • Drug Combinations
  • Pyrazoles
  • Sulfonamides
  • Chondroitin Sulfates
  • Celecoxib
  • Glucosamine
Topics
  • Aged
  • Celecoxib
  • Chondroitin Sulfates (adverse effects, therapeutic use)
  • Cyclooxygenase 2 Inhibitors (adverse effects, therapeutic use)
  • Dietary Supplements
  • Drug Combinations
  • Female
  • Glucosamine (adverse effects, therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Osteoarthritis, Knee (diagnostic imaging, drug therapy)
  • Pain Measurement (methods)
  • Pyrazoles (adverse effects, therapeutic use)
  • Radiography
  • Sulfonamides (adverse effects, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: